Samsung Biologics Inks Landmark $Billions Deal with Leading Asia Pharma Giant

Samsung Biologics, a global leader in contract development and manufacturing (CDMO), announced today that it has secured a USD 1.24 billion manufacturing agreement with a prominent Asia-based pharmaceutical company. This deal, the largest ever signed with a single client, will see production carried out at Samsung Biologics' state-of-the-art facility in Songdo, South Korea, through December 2037. With this latest contract, the company’s total orders for 2024 now exceed USD 3.3 billion, further solidifying its position in the global biomanufacturing industry.

Samsung Biologics has established partnerships with 17 of the top 20 global pharmaceutical companies and is continuously expanding its client base into critical markets such as Japan. With a strong presence in the U.S. through its sales offices, the company is set to open a regional office in Tokyo, aimed at strengthening client relationships. Additionally, Samsung Biologics is nearing the completion of its dedicated ADC facility, expected to be finished by the end of this year.

The company's fifth plant, scheduled to become operational in April 2025, will introduce an additional 180 kL of capacity, bringing the total to 784 kL across its five plants. Committed to addressing emerging health challenges and enhancing patient outcomes, the company continues to roll out cutting-edge CDO platforms and adopt advanced manufacturing technologies. These innovations are designed to support complex projects, including the development and production of multispecific therapies.

John Rim, President and CEO of Samsung Biologics, “We are pleased to strategically collaborate with the Asia-based pharmaceutical company to bring effective, high-quality biopharmaceuticals to the global market. The deal comes at a significant time as we proactively build on our biomanufacturing capacity to readily support our clients. Leveraging our capabilities and proven expertise, we plan to maintain momentum for further expansion by fostering trusted and sustainable partnerships with potential and existing clients for mutual growth, and ultimately help patients with unmet needs.”